Efficacy and Safety of Repeated Subcutaneous Ketamine Injections for Treatment Resistant Depression – The KADS Study: A Randomised, Double-Blind, Comparator-Controlled Trial by Colleen Loo, Nicholas Glozier, David Barton, Bernhard Baune, Natalie Mills, Paul B. Fitzgerald, Paul Glue, Shanthi Sarma, Veronica Galvez-Ortiz, Dusan Hadzi-Pavlovic, Angelo Alonzo, Vanessa Dong, Donel M. Martin, Stevan Nikolin, Philip Mitchell, Michael Berk, Gregory Carter, Maree Hackett, John Leyden, Sean Hood, Andrew Somogyi, Kyle Lapidus, elizabeth stratton, Ellen Lyrtzis, Kirsten Gainsford, Shona Neehoff, Deepak Garg, Nicollette Thornton, Célia Fourrier, Karyn Richardson, Demi Rozakis, Anish Scaria, Cathrine Mihalopoulos, Mary Lou Chatterton, William McDonald, Philip Boyce, Paul Holtzheimer, Frank Andrew Kozel, Patricio Riva-Posse, Anthony Rodgers :: SSRN

Background: Studies suggest efficacy for racemic ketamine and esketamine in treatment resistant depression (TRD), but Phase 3 trials assessing the safety and ef
— Read on papers.ssrn.com/sol3/papers.cfm

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s